CD7-targeted cell therapy for relapsed or refractory T-cell lymphoma or leukemia
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This trial tests a type of immunotherapy that uses specially engineered immune cells to find and attack cancer cells that have a marker called CD7. It is for people with T-cell lymphoma or acute leukemia that has come back or not responded to previous treatments.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have a type of T-cell lymphoma or leukemia that has returned or not improved after at least two standard treatments.
- Your cancer cells must have a marker called CD7, which the therapy targets.
- You are between 14 and 75 years old.
- You are expected to live at least 3 months and are able to carry out daily activities with some help if needed.
- You have adequate organ function (kidney, liver, heart, and lungs) and blood counts that can be supported with transfusions if necessary.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new CAR T-cell therapy targeting CD7, a protein on some blood cancer cells. It is designed for patients whose T-cell leukemia/lymphoma or other CD7-positive blood cancer has not responded to standard treatments or has returned.
This trial tests a new kind of immunotherapy called CD7 CAR-T therapy for people with T-cell cancers (like leukemia or lymphoma) that have come back or not responded to treatment. The CAR-T cells are made from your own immune cells or a donor's, and they are designed to find and destroy cancer cells that carry the CD7 marker.
This trial tests a special immune cell therapy (SupCD7 CART) that targets a protein called CD7 on cancer cells. It is for people with certain types of blood cancers (like T-ALL/LBL or AML) that have come back or not responded to standard treatments.
This trial tests a new treatment called CD7 CAR-T, which uses your own immune cells modified to find and attack cancer cells that have a protein called CD7 on their surface. It's for people with T-cell acute lymphoblastic leukemia or T-cell lymphoblastic lymphoma that has come back or not responded to standard treatments.
This trial tests a new immune therapy called CD7 CAR-T cells for people with acute leukemia that has come back or hasn't gotten better with standard treatments. It aims to see if this treatment is safe and can help control the leukemia.
This trial combines your own stem cells (collected before) with a special immune cell therapy (CD7-CART) to treat T-cell lymphoma or leukemia. It may help people with high-risk or hard-to-treat disease.
Hear when a new CD7+ Lymphoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.